These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 24144230)

  • 1. A fingerprint pair analysis of hERG inhibition data.
    Springer C; Sokolnicki KL
    Chem Cent J; 2013 Oct; 7(1):167. PubMed ID: 24144230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.
    Diaz GJ; Daniell K; Leitza ST; Martin RL; Su Z; McDermott JS; Cox BF; Gintant GA
    J Pharmacol Toxicol Methods; 2004; 50(3):187-99. PubMed ID: 15519905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
    Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
    J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
    Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
    Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel.
    Titus SA; Beacham D; Shahane SA; Southall N; Xia M; Huang R; Hooten E; Zhao Y; Shou L; Austin CP; Zheng W
    Anal Biochem; 2009 Nov; 394(1):30-8. PubMed ID: 19583963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification of drug-induced hERG potassium-channel block from electrocardiographic T-wave features using artificial neural networks.
    Morettini M; Peroni C; Sbrollini A; Marcantoni I; Burattini L
    Ann Noninvasive Electrocardiol; 2019 Nov; 24(6):e12679. PubMed ID: 31347753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
    Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
    Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular determinants of dofetilide block of HERG K+ channels.
    Ficker E; Jarolimek W; Kiehn J; Baumann A; Brown AM
    Circ Res; 1998 Feb; 82(3):386-95. PubMed ID: 9486667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine, and verapamil.
    Vicente J; Johannesen L; Mason JW; Crumb WJ; Pueyo E; Stockbridge N; Strauss DG
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25870186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MICE models: superior to the HERG model in predicting Torsade de Pointes.
    Kramer J; Obejero-Paz CA; Myatt G; Kuryshev YA; Bruening-Wright A; Verducci JS; Brown AM
    Sci Rep; 2013; 3():2100. PubMed ID: 23812503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of models for predicting Torsade de Pointes cardiac arrhythmias using perceptron neural networks.
    Sharifi M; Buzatu D; Harris S; Wilkes J
    BMC Bioinformatics; 2017 Dec; 18(Suppl 14):497. PubMed ID: 29297274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines.
    Lu HR; Vlaminckx E; Hermans AN; Rohrbacher J; Van Ammel K; Towart R; Pugsley M; Gallacher DJ
    Br J Pharmacol; 2008 Aug; 154(7):1427-38. PubMed ID: 18493243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
    Hancox JC; McPate MJ; El Harchi A; Zhang YH
    Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altering extracellular potassium concentration does not modulate drug block of human ether-a-go-go-related gene (hERG) channels.
    Limberis JT; Su Z; Cox BF; Gintant GA; Martin RL
    Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1059-65. PubMed ID: 17042915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.
    Vicente J; Stockbridge N; Strauss DG
    J Electrocardiol; 2016; 49(6):837-842. PubMed ID: 27524478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
    Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
    J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HERG block, QT liability and sudden cardiac death.
    Brown AM
    Novartis Found Symp; 2005; 266():118-31; discussion 131-5, 155-8. PubMed ID: 16050265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart.
    Qu Y; Fang M; Gao B; Chui RW; Vargas HM
    J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
    Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
    Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.